Barclays PLC Erasca, Inc. Transaction History
Barclays PLC
- $327 Billion
- Q2 2024
A detailed history of Barclays PLC transactions in Erasca, Inc. stock. As of the latest transaction made, Barclays PLC holds 47,273 shares of ERAS stock, worth $122,437. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,273
Previous 64,319
26.5%
Holding current value
$122,437
Previous $132,000
15.91%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ERAS
# of Institutions
133Shares Held
205MCall Options Held
3.1KPut Options Held
142K-
Frazier Life Sciences Management, L.P. Menlo Park, CA16.2MShares$42 Million2.26% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$42 Million4.2% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$35.7 Million1.36% of portfolio
-
Arch Venture Management, LLC Chicago, IL11.1MShares$28.6 Million15.29% of portfolio
-
Black Rock Inc. New York, NY10.6MShares$27.5 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $316M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...